All articles by Allie Nawrat

1. BioNTech acquires T cell therapy-focused Neon for $67m

   BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to…
   Read More…

   17 Jan
2. NICE cancer guidance: good news for Ibrance and Lynparza

   Every two minutes someone in the UK is diagnosed with cancer, according to Cancer Research UK statistics. Public Health England…
   Read More…

   16 Jan
3. FDA grants Clovis’ Rubraca fast track designation for prostate cancer

   Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as…
   Read More…

   16 Jan
4. Japan approves ViiV’s two drug regimen Dovato for HIV

   ViiV Healthcare’s human immunodeficiency virus (HIV) drug Dovato (dolutegravir 50mg/lamivudine 300mg) has been approved by the Japanese Ministry of Health,…
   Read More…

   15 Jan
5. MorphoSys and Incyte sign $900m deal for B-cell malignancies drug

   Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the…
   Read More…

   14 Jan
6. AZ to take $100m hit from ending trial of CV drug Epanova

   AstraZeneca (AZ) has announced the termination of its Phase III STRENGTH trial of Epanova (omega-3 carboxylic acids) following a recommendation…
   Read More…

   13 Jan
7. Pfizer signs oncology agreement with STR-focused eFFECTOR

   San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field. The collaboration…
   Read More…

   10 Jan
8. No more siloes: linking rheumatology and CVD with Abcentra

   Cardiovascular disease (CVD) includes any conditions that affect the heart or blood vessels. Treatment of this condition has largely been…
   Read More…

   8 Jan
9. Galen acquires Nordic-based POA Pharma in multi-million pound deal

   Northern Ireland-based, globally focused pharmaceutical sales and marketing firm Galen has acquired Swedish-headquartered POA Pharma in a multi-million pound takeover…
   Read More…

   8 Jan
10. Merck collaborates on small molecule inhibitors with Taiho and Astex

    Merck has signed an exclusive worldwide research collaboration and licence agreement with two Otsuka Pharmaceutical subsidiaries, Japanese Taiho Pharmaceutical and…
    Read More…

    6 Jan